An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

NCT02932891 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: DSXS topical

Sponsor

Sun Pharmaceutical Industries, Inc.